Ciprofloxacin is indicated for the treatment of the following infections caused by sensitive bacteria:
Respiratory tract infections: e.g. lobar and bronchopneumonia, acute and chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis, empyema. Ciprofloxacin is not recommended as first-line therapy for the treatment of pneumococcal pneumonia. Ciprofloxacin may be used for treating Gram-negative pneumonia.
Urinary tract infections: e.g. uncomplicated and complicated urethritis, cystitis, pyelonephritis, prostatitis, epididymitis. Gastro-intestinal infections: e.g. enteric fever, infective diarrhoea.
Children and Adolescents:
Ciprofloxacin may be used for the 2nd and 3rd line treatment of complicated urinary tract infections and pyelonephritis in children and adolescents 1-17 years of age and for the treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa in children and adolescents 5-17 years of age. The use of Cifox in paediatric patients with complicated urinary tract infections and pyelonephritis should be restricted to infections caused by organisms for which Ciprofloxacin is the drug of choice, based on the results of antimicrobial susceptibility testing. Treatment should be initiated by a physician, who is experienced in the treatment of severe infections in children and adolescents and after careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissues.
Inhalation Anthrax in Adults and in Children:
To reduce the incidence or progression of disease following confirmed or suspected exposure to aerosolised Bacillus anthracis.
Download Cifox 250mg SPC here
Download Cifox 500mg SPC here
Download Cifox 750mg SPC here
Download Cifox 2mg/ml Solution for Infusion SPC here
Download Cifox 250mg PIL here
Download Cifox 500mg PIL here
Download Cifox 750mg PIL here
Download Cifox 2mg/ml Solution for Infusion PIL here